Taysha Gene Therapies reports Q3 net loss of $39.1M, advances TSHA-102 toward potential BLA submission

Taysha Gene Therapies posted a Q3 net loss of $39.1M, or $0.10 per share, with no revenue. Cash runway extends into 2H 2028. TSHA-102 safety profile remains clean; manufacturing PPQ completed. Key FDA interactions and interim data expected in 1H 2027.